Research ExplorerPublicationsLoss of membranous VEGFR1 expression is associated with an a...

Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer

Standard

Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer. / Lebok, Patrick; Huber, Julia ; Burandt, Eike-Christian; Lebeau, Annette; Marx, Andreas Holger; Terracciano, Luigi; Heilenkötter, Uwe; Jänicke, Fritz; Müller, Volkmar; Paluchowski, Peter; Geist, Stefan; Wilke, Christian; Simon, Ronald; Sauter, Guido; Quaas, Alexander.

In: MOL MED REP, Vol. 14, No. 2, 08.2016, p. 1443-50.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lebok, P, Huber, J, Burandt, E-C, Lebeau, A, Marx, AH, Terracciano, L, Heilenkötter, U, Jänicke, F, Müller, V, Paluchowski, P, Geist, S, Wilke, C, Simon, R, Sauter, G & Quaas, A 2016, 'Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer', MOL MED REP, vol. 14, no. 2, pp. 1443-50. https://doi.org/10.3892/mmr.2016.5430

APA

Lebok, P., Huber, J., Burandt, E-C., Lebeau, A., Marx, A. H., Terracciano, L., Heilenkötter, U., Jänicke, F., Müller, V., Paluchowski, P., Geist, S., Wilke, C., Simon, R., Sauter, G., & Quaas, A. (2016). Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer. MOL MED REP, 14(2), 1443-50. https://doi.org/10.3892/mmr.2016.5430

Vancouver

Lebok P, Huber J, Burandt E-C, Lebeau A, Marx AH, Terracciano L et al. Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer. MOL MED REP. 2016 Aug;14(2):1443-50. https://doi.org/10.3892/mmr.2016.5430

Bibtex

@article{cf7d611fbf504c17b9fec98b6463beee,
title = "Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer",
abstract = "Angiogenesis is a key process in tumor growth and progression, which is controlled by vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs). In order to better understand the prevalence and prognostic value of VEGFR1 expression in breast cancer, a tissue microarray containing >2,100 breast cancer specimens, with clinical follow‑up data, was analyzed by immunohistochemistry using an antibody directed against the membrane‑bound full‑length receptor protein. The results demonstrated that membranous VEGFR1 staining was detected in all (5 of 5) normal breast specimens. In carcinoma specimens, membranous staining was negative in 3.1%, weak in 6.3%, moderate in 10.9%, and strong in 79.7% of the 1,630 interpretable tissues. Strong staining was significantly associated with estrogen receptor and progesterone receptor expression, but was inversely associated with advanced tumor stage (P=0.0431), high Bloom-Richardson-Ellis Score for Breast Cancer grade and low Ki67 labeling index (both P<0.0001). Cancers with moderate to strong (high) VEGFR1 expression were associated with significantly improved overall survival, as compared with tumors exhibiting negative or weak (low) expression (P=0.0015). This association was also detected in the subset of nodal‑positive cancers (P=0.0018), and in the subset of 185 patients who had received tamoxifen as the sole therapy (P=0.001). In conclusion, these data indicated that membrane‑bound VEGFR1 is frequently expressed in normal and cancerous breast epithelium. In addition, reduced or lost VEGFR1 expression may serve as a marker for poor prognosis in patients with breast cancer, who might not optimally benefit from endocrine therapy.",
keywords = "Journal Article",
author = "Patrick Lebok and Julia Huber and Eike-Christian Burandt and Annette Lebeau and Marx, {Andreas Holger} and Luigi Terracciano and Uwe Heilenk{\"o}tter and Fritz J{\"a}nicke and Volkmar M{\"u}ller and Peter Paluchowski and Stefan Geist and Christian Wilke and Ronald Simon and Guido Sauter and Alexander Quaas",
year = "2016",
month = aug,
doi = "10.3892/mmr.2016.5430",
language = "English",
volume = "14",
pages = "1443--50",
journal = "MOL MED REP",
issn = "1791-2997",
publisher = "Spandidos Publications",
number = "2",

}

RIS

TY - JOUR

T1 - Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer

AU - Lebok, Patrick

AU - Huber, Julia

AU - Burandt, Eike-Christian

AU - Lebeau, Annette

AU - Marx, Andreas Holger

AU - Terracciano, Luigi

AU - Heilenkötter, Uwe

AU - Jänicke, Fritz

AU - Müller, Volkmar

AU - Paluchowski, Peter

AU - Geist, Stefan

AU - Wilke, Christian

AU - Simon, Ronald

AU - Sauter, Guido

AU - Quaas, Alexander

PY - 2016/8

Y1 - 2016/8

N2 - Angiogenesis is a key process in tumor growth and progression, which is controlled by vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs). In order to better understand the prevalence and prognostic value of VEGFR1 expression in breast cancer, a tissue microarray containing >2,100 breast cancer specimens, with clinical follow‑up data, was analyzed by immunohistochemistry using an antibody directed against the membrane‑bound full‑length receptor protein. The results demonstrated that membranous VEGFR1 staining was detected in all (5 of 5) normal breast specimens. In carcinoma specimens, membranous staining was negative in 3.1%, weak in 6.3%, moderate in 10.9%, and strong in 79.7% of the 1,630 interpretable tissues. Strong staining was significantly associated with estrogen receptor and progesterone receptor expression, but was inversely associated with advanced tumor stage (P=0.0431), high Bloom-Richardson-Ellis Score for Breast Cancer grade and low Ki67 labeling index (both P<0.0001). Cancers with moderate to strong (high) VEGFR1 expression were associated with significantly improved overall survival, as compared with tumors exhibiting negative or weak (low) expression (P=0.0015). This association was also detected in the subset of nodal‑positive cancers (P=0.0018), and in the subset of 185 patients who had received tamoxifen as the sole therapy (P=0.001). In conclusion, these data indicated that membrane‑bound VEGFR1 is frequently expressed in normal and cancerous breast epithelium. In addition, reduced or lost VEGFR1 expression may serve as a marker for poor prognosis in patients with breast cancer, who might not optimally benefit from endocrine therapy.

AB - Angiogenesis is a key process in tumor growth and progression, which is controlled by vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs). In order to better understand the prevalence and prognostic value of VEGFR1 expression in breast cancer, a tissue microarray containing >2,100 breast cancer specimens, with clinical follow‑up data, was analyzed by immunohistochemistry using an antibody directed against the membrane‑bound full‑length receptor protein. The results demonstrated that membranous VEGFR1 staining was detected in all (5 of 5) normal breast specimens. In carcinoma specimens, membranous staining was negative in 3.1%, weak in 6.3%, moderate in 10.9%, and strong in 79.7% of the 1,630 interpretable tissues. Strong staining was significantly associated with estrogen receptor and progesterone receptor expression, but was inversely associated with advanced tumor stage (P=0.0431), high Bloom-Richardson-Ellis Score for Breast Cancer grade and low Ki67 labeling index (both P<0.0001). Cancers with moderate to strong (high) VEGFR1 expression were associated with significantly improved overall survival, as compared with tumors exhibiting negative or weak (low) expression (P=0.0015). This association was also detected in the subset of nodal‑positive cancers (P=0.0018), and in the subset of 185 patients who had received tamoxifen as the sole therapy (P=0.001). In conclusion, these data indicated that membrane‑bound VEGFR1 is frequently expressed in normal and cancerous breast epithelium. In addition, reduced or lost VEGFR1 expression may serve as a marker for poor prognosis in patients with breast cancer, who might not optimally benefit from endocrine therapy.

KW - Journal Article

U2 - 10.3892/mmr.2016.5430

DO - 10.3892/mmr.2016.5430

M3 - SCORING: Journal article

C2 - 27357606

VL - 14

SP - 1443

EP - 1450

JO - MOL MED REP

JF - MOL MED REP

SN - 1791-2997

IS - 2

ER -